18 results on '"Denardo, Andrea"'
Search Results
2. The modulation of iron metabolism affects the Rhabdomyosarcoma tumor growth in vitro and in vivo
- Author
-
Asperti, Michela, Cantamessa, Luca, Gryzik, Magdalena, Bugatti, Mattia, Codenotti, Silvia, Denardo, Andrea, Vermi, William, Fanzani, Alessandro, and Poli, Maura
- Published
- 2023
- Full Text
- View/download PDF
3. Quantification of circulating alpha-1-antitrypsin polymers associated with different SERPINA1 genotypes.
- Author
-
Balderacchi, Alice M., Bignotti, Mattia, Ottaviani, Stefania, Denardo, Andrea, Barzon, Valentina, Ben Khlifa, Emna, Vailati, Guido, Piloni, Davide, Benini, Federica, Corda, Luciano, Corsico, Angelo G., Ferrarotti, Ilaria, and Fra, Annamaria
- Subjects
ALPHA 1-antitrypsin deficiency ,LEUCOCYTE elastase ,BLOOD plasma ,GENETIC disorders ,C-reactive protein ,ELASTASES - Abstract
Alpha-1-antitrypsin deficiency is a genetic disorder caused by mutations in the SERPINA1 gene encoding alpha-1-antitrypsin (AAT), the major serine protease inhibitor in plasma. Reduced AAT levels are associated with elevated risk of developing emphysema mainly due to uncontrolled activity of neutrophil elastase in the lungs. The prevalent Z-AAT mutant and many rare pathogenic AAT variants also predispose to liver disease due to their accumulation as polymeric chains in hepatocytes. Part of these polymers are secreted into the bloodstream and could represent biomarkers of intra-hepatic accumulation. Moreover, being inactive, they further lower lung protection against proteases. Aim of our study is to accurately quantify the percentage of circulating polymers (CP) in a cohort of subjects with different SERPINA1 genotypes. CP concentration was measured in plasma or Dried Blood Spot (DBS) by a sensitive sandwich ELISA based on capture by the polymer-specific 2C1 monoclonal antibody. CP were significantly elevated in patients with the prevalent PI*SZ and PI*ZZ genotypes, with considerable intra-genotype variability. Notably, higher percentage of polymers was observed in association with elevated C-reactive protein. CP levels were also increased in carriers of the M
malton variant, and of Mprocida , I, Plowell and Mherleen in heterozygosity with Z-AAT. These findings highlight the importance of implementing CP quantification in a clinical laboratory. Indeed, the variable amount of CP in patients with the same genotype may correlate with the variable severity of the associated lung and liver diseases. Moreover, CP can reveal the polymerogenic potential of newly discovered ultrarare AAT variants. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
4. Functional characterization of amino acid variants of the reactive-center-loop of alpha-1-antitrypsin
- Author
-
BEN KHLIFA, Emna, Bignotti, Mattia, Bartoli, Giulia, Denardo, Andrea, and Fra, Annamaria
- Published
- 2022
5. Iron distribution in different tissues of homozygous Mask (msk/msk) mice and the effects of oral iron treatments.
- Author
-
Asperti, Michela, Brilli, Elisa, Denardo, Andrea, Gryzik, Magdalena, Pagani, Francesca, Busti, Fabiana, Tarantino, Germano, Arosio, Paolo, Girelli, Domenico, and Poli, Maura
- Published
- 2021
- Full Text
- View/download PDF
6. HEPARIN BINDING DOMAINS IN BMP6: STUDY ON THE SYNTHETIC PEPTIDES AND THE RECOMBINANT PROTEIN
- Author
-
Ruzzenenti, P, Denardo, Andrea, Carmona, F, Federici, S, Asperti, M, Bergese, P, Poli, M, and Arosio, P
- Published
- 2017
7. Production of recombinant human BMP6 and peptides for the study of heparin binding activity
- Author
-
Denardo, Andrea and Carmona, Fernando
- Published
- 2016
- Full Text
- View/download PDF
8. S283: THE NON-ANTICOAGULANT HEPARINOID COMPOUND, SEVUPARIN, STRONGLY REDUCES HEPCIDIN EXPRESSION IN CELLS, IN MICE AND IN HEALTHY VOLUNTEERS.
- Author
-
Asperti, Michela, Denardo, Andrea, Gryzik, Magdalena, Persson, Kristina E. M., Westerberg, Göran, Öhd, John, and Poli, Maura
- Published
- 2023
- Full Text
- View/download PDF
9. BMP6 binding to heparin and heparan sulfate is mediated by N-terminal and C-terminal clustered basic residues.
- Author
-
Denardo, Andrea, Elli, Stefano, Federici, Stefania, Asperti, Michela, Gryzik, Magdalena, Ruzzenenti, Paola, Carmona, Fernando, Bergese, Paolo, Naggi, Annamaria, Arosio, Paolo, and Poli, Maura
- Subjects
- *
HEPARAN sulfate , *BONE morphogenetic proteins , *IMMOBILIZED proteins , *HEPARIN , *MOLECULAR dynamics , *PEPTIDE hormones - Abstract
The bone morphogenetic protein 6 (BMP6) is a crucial inducer of hepcidin, the peptide hormone that regulates the iron availability in our body. Hepcidin expression is influenced by hepatic heparan sulfate (HS) and by heparin administration, suggesting BMP6 interaction with heparin/HS. The BMP2/4 subfamily has been deeply characterized to have a N-terminal heparin/HS binding domain (HBD), whose basic residues contact the sulfate groups on heparin and HS. Such detailed characterization is still required for other, structurally different BMPs, including BMP6. BMP6 peptides encompassing potential HBDs were analysed on heparin-functionalized plates and microcantilevers, and on membrane HS expressing CHO-K1 cells. Monomeric wild-type BMP6 and mutants were produced, substituting the basic residues with non-charged ones, and their affinity to the heparin-column was measured. The BMP6-heparin interaction was also predicted at atomic level by in silico molecular dynamics. N-terminal and C-terminal BMP6 peptides showed high heparin affinity in solid-phase assays. The mutation of the two sites (R5L, R6S, R7L and K126N, K127N, R129S) abolished the heparin-binding activity of the recombinant monomeric BMP6. Monomeric BMP6 and peptides specifically bound to membrane HS of CHO-K1 cells through the same domains. Molecular dynamic studies supported the role of the two HBDs, suggesting a cooperative behaviour. In BMP6, N-terminal (R5, R6, R7) and C-terminal (K126, K127, R129) domains mediate the interaction with heparin and HS. This study provides the molecular mechanism supporting the use of heparin to sequester BMP6 and inhibit hepcidin expression, a novel clinical approach for high-hepcidin iron disorders. • Arginine- and Lysine-rich regions were identified on BMP6 as potential heparin/HS-binding domains (HBDs). • BMP6 peptides and recombinant protein bound immobilized heparin and HS. • We dissected two heparin binding sites on BMP6: the N-terminal R5 R6 R7 and the C-terminal K126 K127 R129. • In in silico study the N-terminus flexibly adapted to heparin and the C-terminus strongly contributed to binding energy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Pentosan polysulfate to control hepcidin expression in vitro and in vivo.
- Author
-
Asperti, Michela, Denardo, Andrea, Gryzik, Magdalena, Castagna, Annalisa, Girelli, Domenico, Naggi, Annamaria, Arosio, Paolo, and Poli, Maura
- Subjects
- *
HEPCIDIN , *MOLECULAR weights , *IRON deficiency , *SULFATION , *BINDING sites , *ENOXAPARIN - Abstract
Hepcidin peptide is crucial in the regulation of systemic iron availability controlling its uptake from the diet and its release from the body storage tissues. Hepcidin dysregulation causes different human disorders ranging from iron overload (e.g. hemochromatosis) to iron deficiency (e.g. anemia). Hepcidin excess is common in the Anemia of Chronic Diseases or Anemia of Inflammation and in the genetic form of anemia named IRIDA; the pharmacological downregulation of hepcidin in these disorders could improve the anemia. Commercial heparins were shown to be strong inhibitors of hepcidin expression, by interfering with BMP6/SMAD pathway. The non-anti-coagulant heparins, modified to abolish the anti-thrombin binding site, were equally potent and could be used to improve iron status. To perform its anti-hepcidin activity heparin needs 2O- and 6O-sulfation and an average molecular weight (MW) up to 4000–8000 Dalton, depending on the sulfation level. The pentosane polysulfate (PPS), which shares with heparin a high degree of sulfation, is a compound with low anti-coagulant activity that is already in use for pharmaceutical treatment. In the present work we analyzed the anti-hepcidin activity of PPS in vitro and in vivo. We found that it acts as a strong inhibitor of hepcidin expression in HepG2 cells with an effect already visible after 2–3 h of treatment. It also suppressed hepcidin in mice in a dose dependent manner after 3 h and with a significant redistribution of systemic iron without evident side effects. PPS is also able to abolish the LPS dependent hepcidin upregulation similarly to that showed for heparin derivatives. These results suggest PPS as an interesting compound to control hepcidin in vivo. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. The Antitumor Didox Acts as an Iron Chelator in Hepatocellular Carcinoma Cells.
- Author
-
Asperti, Michela, Cantamessa, Luca, Ghidinelli, Simone, Gryzik, Magdalena, Denardo, Andrea, Giacomini, Arianna, Longhi, Giovanna, Fanzani, Alessandro, Arosio, Paolo, and Poli, Maura
- Subjects
IRON chelates ,HEPATOCELLULAR carcinoma ,CATECHOL ,RIBONUCLEOSIDE diphosphate reductase ,CELL proliferation ,CELL death - Abstract
Ribonucleotide reductase (RR) is the rate-limiting enzyme that controls the deoxynucleotide triphosphate synthesis and it is an important target of cancer treatment, since it is expressed in tumor cells in proportion to their proliferation rate, their invasiveness and poor prognosis. Didox, a derivative of hydroxyurea (HU), is one of the most potent pharmaceutical inhibitors of this enzyme, with low in vivo side effects. It inhibits the activity of the subunit RRM2 and deoxyribonucleotides (dNTPs) synthesis, and it seems to show iron-chelating activity. In the present work, we mainly investigated the iron-chelating properties of didox using the HA22T/VGH cell line, as a model of hepatocellular carcinoma (HCC). We confirmed that didox induced cell death and that this effect was suppressed by iron supplementation. Interestingly, cell treatments with didox caused changes of cellular iron content, TfR1 and ferritin levels comparable to those caused by the iron chelators, deferoxamine (DFO) and deferiprone (DFP). Chemical studies showed that didox has an affinity binding to Fe
3+ comparable to that of DFO and DFP, although with slower kinetic. Structural modeling indicated that didox is a bidentated iron chelator with two theoretical possible positions for the binding and among them that with the two hydroxyls of the catechol group acting as ligands is the more likely one. The iron chelating property of didox may contribute to its antitumor activity not only blocking the formation of the tyrosil radical on Tyr122 (such as HU) on RRM2 (essential for its activity) but also sequestering the iron needed by this enzyme and to the cell proliferation. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
12. NCOA4-mediated ferritinophagy promotes ferroptosis induced by erastin, but not by RSL3 in HeLa cells.
- Author
-
Gryzik, Magdalena, Asperti, Michela, Denardo, Andrea, Arosio, Paolo, and Poli, Maura
- Subjects
- *
TRANSFERRIN , *FERRITIN , *HELA cells , *GLYCERALDEHYDEPHOSPHATE dehydrogenase , *TRANSFERRIN receptors , *UBIQUINONES , *GLUTATHIONE peroxidase , *HEME oxygenase - Abstract
Ferroptosis is a regulated cell death characterized by a lethal accumulation of lipid peroxides due to an increase of intracellular iron and a decrease of antioxidant capacity. The reduction of antioxidant activity is obtained by using chemical agents, such as erastin and RSL3, the first one inhibiting the transmembrane cystine-glutamate antiporter causing a cysteine and glutathione depletion and the second one inactivating directly the glutathione peroxidase 4 (GPX4) respectively. The role of iron and its related proteins in supporting the formation of lipid peroxides, is not completely understood hence to try to shed light on it we generated HeLa clones with altered ferritinophagy, the ferritin degradation process, by knocking-out or overexpressing Nuclear Receptor Coactivator 4 (NCOA4), the ferritin autophagic cargo-receptor. NCOA4 deficiency abolished ferritinophagy increasing ferritin level and making the cells more resistant to erastin, but unexpectedly more sensitive to RSL3. Interestingly, we found that erastin promoted ferritinophagy in HeLa cells expressing NCOA4, increasing the free iron, lipid peroxidation and the sensitivity to ferroptosis. In contrast, RSL3 did not modulate ferritinophagy, while NCOA4 overexpression delayed RSL3-induced cell death suggesting that RSL3 mechanism of action is independent of ferritin degradation process. Therefore, the ferritin-iron release in the execution of ferroptosis seems to depend on the inducing compound, its target and downstream pathway of cell death activation. Unlabelled Image • Erastin induces NCOA4-mediated ferritinophagy for ferroptosis execution • RSL3-mediated ferroptotic cell death does not involve ferritin degradation • NCOA4 expression and/or active ferritinophagy delay RSL3-induced ferroptosis Abbrevations. Unlabelled Table BH 4 tetrahydrobiopterin CoQ 10 coenzyme Q 10 Cys cysteine Cys-Cys cystine DFO desferoxamine ER erastin FAC ferric ammonium citrate Fer-1 ferrostatin-1 FSP1 ferroptosis suppressor protein 1 FTH ferritin heavy chain FTL ferritin light chain FPN ferroportin GAPDH glyceraldehyde 3-phosphate dehydrogenase GCH1 GTP cyclohydrolase-1 Glu glutamine GPX4 glutathione peroxidase 4 GSH glutathione GSSG oxidized glutathione HO-1 heme oxygenase 1 LC3 (MAP1LC3) microtubule-associated protein 1 light chain 3 LIP labile iron pool LOX5 lipoxygenase 5 NCOA4 nuclear receptor coactivator 4 NRF2 nuclear factor erythroid 2 (NFE2)-related factor 2 NQO1 NAD(P)H quinone dehydrogenase 1 ROS reactive oxygen species RSL3 RAS-selective lethal 3 TfR1 transferrin receptor 1 TxnR thioredoxin reductase 1 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Hepatic heparan sulfate is a master regulator of hepcidin expression and iron homeostasis in human hepatocytes and mice.
- Author
-
Poli, Maura, Anower-E-Khuda, Ferdous, Asperti, Michela, Ruzzenenti, Paola, Gryzik, Magdalena, Denardo, Andrea, Gordts, Philip L. S. M., Arosio, Paolo, and Esko, Jeffrey D.
- Abstract
Hepcidin is a liver-derived peptide hormone that controls systemic iron homeostasis. Its expression is regulated by the bone morphogenetic protein 6 (BMP6)/SMAD1/5/8 pathway and by the proinflammatory cytokine interleukin 6 (IL6). Proteoglycans that function as receptors of these signaling proteins in the liver are commonly decorated by heparan sulfate, but the potential role of hepatic heparan sulfate in hepcidin expression and iron homeostasis is unclear. Here, we show that modulation of hepatic heparan sulfate significantly alters hepcidin expression and iron metabolism both in vitro and in vivo. Specifically, enzymatic removal of heparan sulfate from primary human hepatocytes, CRISPR/Cas9 manipulation of heparan sulfate biosynthesis in human hepatoma cells, or pharmacological manipulation of heparan sulfate–protein interactions using sodium chlorate or surfen dramatically reduced baseline and BMP6/SMAD1/5/8-dependent hepcidin expression. Moreover inactivation of the heparan sulfate biosynthetic gene N-deacetylase and N-sulfotransferase 1 (Ndst1) in murine hepatocytes (Ndst1f/fAlbCre+) reduced hepatic hepcidin expression and caused a redistribution of systemic iron, leading to iron accumulation in the liver and serum of mice. Manipulation of heparan sulfate had a similar effect on IL6-dependent hepcidin expression in vitro and suppressed IL6-mediated iron redistribution induced by lipopolysaccharide in vivo. These results provide compelling evidence that hepatocyte heparan sulfate plays a key role in regulating hepcidin expression and iron homeostasis in mice and in human hepatocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Characterization of Novel Alpha-1-Antitrypsin Coding Variants in a Mammalian Cellular Model.
- Author
-
Denardo A, Ben Khlifa E, Bignotti M, and Fra A
- Subjects
- Animals, Humans, HEK293 Cells, Cloning, Molecular, Technology, Mammals, Nucleic Acid Amplification Techniques, Polymers
- Abstract
Advances in genetic screening technologies have considerably accelerated the discovery of rare alpha-1-antitrypsin (AAT) variants. Expression in cellular models is an effective approach to evaluate the pathogenic potential of these new AAT variants, whose clinical significance would otherwise remain uncertain. Here we provide a detailed description of established methods for in vitro characterization of AAT coding variants expressed in HEK293T/17 cells. The protocols include determination of secretion efficiency, the tendency to form polymeric chains and the anti-elastase inhibitory activity., (© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
15. Probing of the reactive center loop region of alpha-1-antitrypsin by mutagenesis predicts new type-2 dysfunctional variants.
- Author
-
Denardo A, Ben Khlifa E, Bignotti M, Giuliani R, D'Acunto E, Miranda E, Irving JA, and Fra A
- Subjects
- Humans, Mutation genetics, Lung, Amino Acid Substitution, alpha 1-Antitrypsin Deficiency genetics, Lung Diseases
- Abstract
Lung disease in alpha-1-antitrypsin deficiency (AATD) mainly results from insufficient control of the serine proteases neutrophil elastase (NE) and proteinase-3 due to reduced plasma levels of alpha-1-antitrypsin (AAT) variants. Mutations in the specificity-determining reactive center loop (RCL) of AAT would be predicted to minimally affect protein folding and secretion by hepatocytes but can impair anti-protease activity or alter the target protease. These properly secreted but dysfunctional 'type-2' variants would not be identified by common diagnostic protocols that are predicated on a reduction in circulating AAT. This has potential clinical relevance: in addition to the dysfunctional Pittsburgh and Iners variants reported previously, several uncharacterized RCL variants are present in genome variation databases. To prospectively evaluate the impact of RCL variations on secretion and anti-protease activity, here we performed a systematic screening of amino acid substitutions occurring at the AAT-NE interface. Twenty-three AAT variants that can result from single nucleotide polymorphisms in this region, including 11 present in sequence variation databases, were expressed in a mammalian cell model. All demonstrated unaltered protein folding and secretion. However, when their ability to form stable complexes with NE was evaluated by western blot, enzymatic assays, and a novel ELISA developed to quantify AAT-NE complexes, substrate-like and NE-binding deficient dysfunctional variants were identified. This emphasizes the ability of the RCL to accommodate inactivating substitutions without impacting the integrity of the native molecule and demonstrates that this class of molecule violates a generally accepted paradigm that equates circulating levels with functional protection of lung tissue., (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Published
- 2023
- Full Text
- View/download PDF
16. The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection.
- Author
-
Sandoval DR, Clausen TM, Nora C, Cribbs AP, Denardo A, Clark AE, Garretson AF, Coker JKC, Narayanan A, Majowicz SA, Philpott M, Johansson C, Dunford JE, Spliid CB, Golden GJ, Payne NC, Tye MA, Nowell CJ, Griffis ER, Piermatteo A, Grunddal KV, Alle T, Magida JA, Hauser BM, Feldman J, Caradonna TM, Pu Y, Yin X, McVicar RN, Kwong EM, Weiss RJ, Downes M, Tsimikas S, Smidt AG, Ballatore C, Zengler K, Evans RM, Chanda SK, Croker BA, Leibel SL, Jose J, Mazitschek R, Oppermann U, Esko JD, Carlin AF, and Gordts PLSM
- Abstract
We identify the prolyl-tRNA synthetase (PRS) inhibitor halofuginone
1 , a compound in clinical trials for anti-fibrotic and anti-inflammatory applications2 , as a potent inhibitor of SARS-CoV-2 infection and replication. The interaction of SARS-CoV-2 spike protein with cell surface heparan sulfate (HS) promotes viral entry3 . We find that halofuginone reduces HS biosynthesis, thereby reducing spike protein binding, SARS-CoV-2 pseudotyped virus, and authentic SARS-CoV-2 infection. Halofuginone also potently suppresses SARS-CoV-2 replication post-entry and is 1,000-fold more potent than Remdesivir4 . Inhibition of HS biosynthesis and SARS-CoV-2 infection depends on specific inhibition of PRS, possibly due to translational suppression of proline-rich proteins. We find that pp1a and pp1ab polyproteins of SARS-CoV-2, as well as several HS proteoglycans, are proline-rich, which may make them particularly vulnerable to halofuginone's translational suppression. Halofuginone is orally bioavailable, has been evaluated in a phase I clinical trial in humans and distributes to SARS-CoV-2 target organs, including the lung, making it a near-term clinical trial candidate for the treatment of COVID-19.- Published
- 2021
- Full Text
- View/download PDF
17. Correction: Hepatic heparan sulfate is a master regulator of hepcidin expression and iron homeostasis in human hepatocytes and mice.
- Author
-
Poli M, Anower-E-Khuda F, Asperti M, Ruzzenenti P, Gryzik M, Denardo A, Gordts PLSM, Arosio P, and Esko JD
- Published
- 2020
- Full Text
- View/download PDF
18. The role of heparin, heparanase and heparan sulfates in hepcidin regulation.
- Author
-
Asperti M, Denardo A, Gryzik M, Arosio P, and Poli M
- Subjects
- Animals, Gene Expression Regulation, Hepcidins genetics, Humans, Glucuronidase metabolism, Heparin metabolism, Heparitin Sulfate metabolism, Hepcidins metabolism
- Abstract
Hepcidin is considered the major regulator of systemic iron homeostasis in human and mice, and its expression in the liver is mainly regulated at a transcriptional level. Central to its regulation are the bone morphogenetic proteins, particularly BMP6, that are heparin binding proteins. Heparin was found to inhibit hepcidin expression and BMP6 activity in hepatic cell lines and in mice, suggesting that endogenous heparan sulfates are involved in the pathway of hepcidin expression. This was confirmed by the study of cells and mice overexpressing heparanase, the enzyme that hydrolyzes heparan sulfates, and by cellular models with altered heparan sulfates. The evidences supporting the role of heparan sulfate in hepcidin expression are summarized in this chapter and open the way for new understanding in hepcidin expression and its control in pathological condition., (© 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.